🔍 Why Many Unpartnered Assets Could Succeed with Innovative Commercial Strategy. Great start to this year's Swiss HLG annual meeting 🧬
Excited to share key insights from Ed Salzman's recent presentation! 🌟
Myth 1: Unpartnered Phase 3 assets are ultra-high risk or poor quality.
Reality: Pharma's diligence isn’t foolproof. High-quality assets often remain unpartnered because they address smaller markets. 🚫🔬
Myth 2: Biotechs should only focus on discovery and development, leaving commercialization to big pharma.
Reality: The commercial landscape is evolving rapidly, especially in the US. Biotechs like Genentech, Regeneron, and Vertex have proven they can successfully commercialize breakthrough therapies, even when pharma deems these "off strategy." 🚀🔬
Myth 3 - not really a myth, unfortunately: Investors prefer quick exits over building companies for the long haul.
Reality: While many investors prioritize rapid exits, this approach can undermine the potential for sustainable growth and commercial success. 📉
The Commercialization Challenge:
Biotechs often lack the commercial culture and experience needed for successful market entry. They’re typically unprepared for the complexities of commercialization, leading to poor shareholder value post-approval. 📊
The Path Forward:
- Building a Commercial Culture: Embrace commercial innovation early, even if it requires leadership changes.
- Investor Alignment: Shift focus from quick exits to long-term growth and value creation.
- Commercial Strategy: Invest in commercial expertise and infrastructure to navigate the changing landscape.
Let’s rethink the strategy and unleash the true potential of innovative biotech assets! 💡🔬
